Zacks Touts Tempus AI Growth, but DeepValue Report Underscores Profitability and Cash Flow Risks

What happened

A Zacks Investment Research article highlights Tempus AI's dual-engine model driving $1.27B in revenues, with diagnostics dominating and data monetization accelerating growth and pricing leverage. However, the DeepValue master report reveals that while Tempus exited 2025 with strong revenue growth—FY2025 at $1.3B, up 83.4% year-over-year—profitability remains precarious, with Adjusted EBITDA just turning positive in Q4 2025 at $12.9M and a full-year guide of ~$65M for FY2026. The report details persistent cash burn, with net cash used in operating activities worsening to $(181.3M) for the nine months ended September 2025, and accounts receivable surging to $311.2M from $154.8M year-over-year, indicating poor revenue-to-cash conversion. Key risks include potential dilution from past ATM sales of $195.5M, acquisition accounting sensitivities flagged by auditors for Ambry's goodwill and intangibles, and the need to sustain diagnostics volume growth (oncology +29% YoY, hereditary +23% YoY in Q4 2025) without deceleration. Investors must therefore look beyond the optimistic narrative to upcoming quarterly prints that confirm the path to profitability and contract durability, as emphasized in the DeepValue analysis.

Implication

The Zacks article adds no new material data, reinforcing that Tempus AI's growth is already priced in, but the DeepValue report underscores critical vulnerabilities: cash burn remains elevated despite revenue scale, and the company relies on continued volume momentum and contract renewals to justify its valuation. Upcoming quarters must show sustained positive Adjusted EBITDA after Q4 2025's $12.9M to maintain credibility for the FY2026 guide of ~$65M, while diagnostics volumes and MRD ramp must avoid deceleration to prevent a growth engine breakdown. Monitoring points include accounts receivable trends, Remaining Contract Value stability above $1.1B, and any equity issuance that could signal failed cash conversion, with failure in these areas risking a re-rate to a cash-burn diagnostics model. Position sizing should be cautious, assuming fundamentals drive outcomes given limited margin of safety from high goodwill and intangibles, and investors should prepare to exit if negative EBITDA re-emerges or volume growth materially slows by mid-2026. Ultimately, the stock's potential hinges on converting 'AI narrative' into repeatable operating leverage, a thesis unchanged by the latest promotional coverage.

Thesis delta

The Zacks article does not alter the core investment thesis from the DeepValue report, as it merely echoes known growth metrics without addressing profitability or cash flow concerns. The thesis remains centered on Tempus AI's ability to deliver on its FY2026 Adjusted EBITDA guide of ~$65M and sustain volume growth without additional dilution, with no shift implied by this new, surface-level coverage.